PSYBIO THERAP. (SUB.VT.) Logo
CA6936971044

PSYBIO THERAP. (SUB.VT.)

Ins Portfolio

Kurse werden geladen...

 Anzeige

Prognose

Für dieses Unternehmen liegen uns keine Analysten-Daten vor.

Scoring-Modelle

Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.

News

  • Foto von PsyBio Therapeutics Awarded Approval to Manufacture Biosynthetic Tryptamines at Scale

    PsyBio Therapeutics Awarded Approval to Manufacture Biosynthetic Tryptamines at Scale

    PsyBio continues to develop psycho-targeted, biosynthesized tryptamines and with this authorization becomes the first biotechnology company to obtain government sanctioned, formal, written authorization to manufacture biosynthetic tryptamines including PsyBio-11142 at scale Oxford, Ohio and Denver, Colorado--(Newsfile Corp. - July 21, 2023) - PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) ("PsyBio" or the "Company"), an intellectual property driven biotechnology company focused upon discovery and development of novel, bespoke, psycho-targeted therapeutics to potentially improve mental and neurological health, today announces that it has received government sanctioned, formal written approval to manufacture PsyBio's proprietary biosynthetic tryptamines. "PsyBio has worked diligently to achieve formal written approval to allow full scale manufacturing of its proprietary biosynthetic tryptamines, including our lead compound PsyBio-11142, which is the penultimate step in moving that first psycho-targeted therapeutic candidate into human clinical trials with the goal to potentially improve mental and neurological health.» Mehr auf newsfilecorp.com

  • Foto von PsyBio Therapeutics successfully completes first pre-IND meeting with the FDA

    PsyBio Therapeutics successfully completes first pre-IND meeting with the FDA

    PsyBio Therapeutics Corp has announced the successful completion of its initial pre-Investigational New Drug (IND) application meeting with the US Food and Drug Administration (FDA) as part of the regulatory submission process.  The company said the focus of the pre-IND meeting was to discuss potential indications, manufacturing strategy, and obtain regulatory guidance as it guides its technology forward towards regulatory approval.» Mehr auf companies

  • Foto von PsyBio Therapeutics presents 16 scientific abstracts highlighting its research and development efforts at two scientific conferences

    PsyBio Therapeutics presents 16 scientific abstracts highlighting its research and development efforts at two scientific conferences

    PsyBio Therapeutics Corp said it presented 16 abstracts highlighting the biotechnology company's research and development initiatives at two scientific conferences. The abstracts covered topics such as biosynthetic pathway and transcriptional methodologic development; evaluation; screening and optimization of systems and organisms, and increasing bioproduction yields of natural and non-natural products.» Mehr auf companies

Unternehmenszahlen

Im letzten Jahr hatte PSYBIO THERAP. (SUB.VT.) einen Umsatz von 0,00 und ein Nettoeinkommen von 4,56 Mio
(EUR)2022
YOY
Umsatz0,00-
Bruttoeinkommen46,61k15,19%
Nettoeinkommen4,56 Mio52,99%
EBITDA4,22 Mio-

Fundamentaldaten

MetrikWert
Marktkapitalisierung
+908,23k
Anzahl Aktien
9,36 Mrd
52 Wochen-Hoch/Tief
+0,0204 - +0,0000971
DividendenNein
Beta
0,66
KGV (PE Ratio)
0,00
KGWV (PEG Ratio)
0,00
KBV (PB Ratio)
0,01
KUV (PS Ratio)
0,00

Unternehmensprofil

PsyBio Therapeutics Corp. ist ein Biotechnologieunternehmen, das sich auf die Erforschung, Entwicklung und Vermarktung von psychedelisch inspirierten regulierten Medikamenten zur Behandlung von psychischen und anderen Störungen in den Vereinigten Staaten konzentriert. Der Hauptsitz des Unternehmens befindet sich in Coconut Creek, Florida.

Name
PSYBIO THERAP. (SUB.VT.)
CEO
Evan Mike Levine
SitzCoconut Creek, fl
USA
Website
Börsengang
25.02.2021
Mitarbeiter4

Ticker Symbole

BörseSymbol
Pnk
PSYBF
München
PSYB.MU
🍪

Parqet nutzt Cookies.Erfahre Mehr